

Docket No. R-237.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 25 2002

TECH CENTER 1600/2900

In re application of: SCHEIFLINGER *et al.*
Serial No: 09/661,992
Filed: 09/14/2000
For: Factor IX/Factor IXa Activating Antibodies
And Antibody Derivatives

Group No.: 1633
Examiner: To be assigned

Assistant Commissioner for Patents
Washington, D. C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith is a Request for Correction of Filing Receipt.

The correct foreign Application reference should read --AUSTRIA A1576/99 09/14/1999--.

In the title of application, please change "Factor IX/Factor Ixa" to --Factor IX/Factor IXa--.

Respectfully submitted,

Michael F. Fedrick
Reg. No. 36,799
Telephone: (818) 550-4569

Baxter Healthcare Corporation
P. O. Box 15210
Irvine, CA 92623-5210

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this document (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. **EL800475175US** in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on **February 6, 2002**.

By

Diane Branham


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of SCHEIFLINGER et al.

Serial No: 09/661,992

Filed: 09/14/2000

For: Factor IX/Factor IXa Activating Antibodies
And Antibody Derivatives



Group No.: 1633

Examiner: To be assigned

RECEIVED
FEB 25 2002
TECH CENTER 1600 290

Assistant Commissioner for Patents
Washington, D. C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a redlined copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error in that the following data is:

- ☒ incorrectly entered
and/or

- ☐ omitted
Error in

1. ☐ Applicant's name
2. ☐ Applicants' addresses
3. ☒ Title
4. ☐ Filing Date
5. ☐ Serial Number
6. ☒ Foreign/PCT Application Reference
7. ☐ Other

Correct Data

- 1.
- 2.
3. Factor IX/Factor IXa Activating Antibodies
and Antibody Derivatives
- 4.
- 5.
6. AUSTRIA A1576/99 09/14/1999
- 7.

3.


- A. ☐ The correction is not due to any error by applicant and no fee is believed to be due; however, the Commissioner is authorized to charge any fees which may become due to Deposit Account No. 02-1437 (R-237.00).

OR

- B. ☒ At least one of the above corrections is due to applicant's error and the fee under 37 CFR 1.19(h) of \$30.00 is paid as follows: charge Deposit Account No. 02-1437 (R-237.00) in the amount of \$30.00. The Commissioner is authorized to charge any additional fees which may be due, or credit any overpayment, to Deposit Account No. 02-1437 (R-237.00).

Baxter Healthcare Corporation
P. O. Box 15210
Irvine, CA 92623-5210

Michael F. Fedrick
Reg. No. 36,799
Telephone: (818) 550-4569



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D. C. 20230
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/661,992	09/14/2000	.1633	892	237 00	61	24	2

Michael C Schiffer
Baxter Healthcare Corporation
P O Box 15210
Irvine, CA 92614

FILING RECEIPT



OC000000005906449

RECEIVED

FEB 25 2002

Date Mailed: 03/27/2001

TECH CENTER 1600/2900

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Friedrich Scheifflinger, Vienna, AUSTRIA;
Randolf Kerschbaumer, Vienna, AUSTRIA;
Falko-Guenter Falkner, Orth/Donau, AUSTRIA;
Friedrich Dorner, Vienna, AUSTRIA;
Hans-Peter Schwarz, Vienna, AUSTRIA;

Continuing Data as Claimed by Applicant

Foreign Applications

A1576/99
AUSTRIA **[A157600]** 09/14/1999

If Required, Foreign Filing License Granted 11/14/2000

Title

IXa
Factor IX/factor **[IXa]** activating antibodies and antibody derivatives

Preliminary Class

424

Data entry by : HOPKINS, AUDREY

Team : OIPE

Date: 03/27/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231